Search results

692 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter

Rehabilitation after traumatic injury

In development [GID-NG10105] Expected publication date: 23 November 2021

Type

NICE guideline

Status

In development
Chronic pain: assessment and management

In development [GID-NG10069] Expected publication date: TBC

Type

NICE guideline

Status

In development
Hypertension in adults: diagnosis and management (update)

In development [GID-NG10177] Expected publication date: 19 April 2023

Type

NICE guideline

Status

In development
Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 25 May 2022

Type

NICE guideline

Status

In development
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management

In development [GID-NG10185] Expected publication date: TBC

Type

NICE guideline

Status

In development
Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 30 June 2021

Type

NICE guideline

Status

In development
Inducing labour (update)

In development [GID-NG10082] Expected publication date: 14 October 2021

Type

NICE guideline

Status

In development
Caesarean section (update)

In development [GID-NG10081] Expected publication date: 31 March 2021

Type

NICE guideline

Status

In development
Subarachnoid haemorrhage due to ruptured aneurysms

In development [GID-NG10097] Expected publication date: 21 July 2021

Type

NICE guideline

Status

In development
Neonatal infection: antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 12 April 2021

Type

NICE guideline

Status

In development
Weight Management

In development [GID-NG10182] Expected publication date: 22 June 2022

Type

NICE guideline

Status

In development
Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 25 August 2021

Type

NICE guideline

Status

In development
Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 22 June 2022

Type

NICE guideline

Status

In development
Barrett's oesophagus: ablative therapy

In development [GID-NG10165] Expected publication date: 23 January 2023

Type

NICE guideline

Status

In development
Depression in adults: treatment and management (update)

In development [GID-CGWAVE0725] Expected publication date: 12 May 2022

Type

NICE guideline

Status

In development
Self harm: assessment, management and preventing recurrence

In development [GID-NG10148] Expected publication date: 18 May 2022

Type

NICE guideline

Status

In development
Gout: diagnosis and management

In development [GID-NG10151] Expected publication date: 13 June 2022

Type

NICE guideline

Status

In development
Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 09 December 2021

Type

NICE guideline

Status

In development
Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management

In development [GID-NG10149] Expected publication date: 08 June 2022

Type

NICE guideline

Status

In development
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: TBC

Type

NICE guideline

Status

In development
Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 08 September 2021

Type

NICE guideline

Status

In development
Atrial fibrillation: management

In development [GID-NG10100] Expected publication date: 12 March 2021

Type

NICE guideline

Status

In development
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 21 April 2021

Type

NICE guideline

Status

In development
Intrapartum care for healthy women and babies (update)

In development [GID-NG10174] Expected publication date: 22 March 2023

Type

NICE guideline

Status

In development
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

Proposed [GID-TA10667] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia [ID3831]

Proposed [GID-TA10736] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Proposed [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating hypereosinophilic syndrome [ID3749]

Proposed [GID-TA10755] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]

Proposed [GID-TA10714] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amivantamab for non-small cell lung cancer [ID3836]

Proposed [GID-TA10729] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Proposed [GID-TA10658] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed